L-Dopa plasma levels variability in Parkinson's disease

被引：0
|
作者：
Albani, G.
Cattaldo, S.
Mauro, A.
机构：
来源：
PARKINSONISM & RELATED DISORDERS | 2007年 / 13卷
关键词：
D O I：
10.1016/S1353-8020(08)70687-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [21] Steady L-DOPA blood levels via transdermal delivery of L-DOPA prodrugs; A novel skin patch for the treatment of Parkinson's disease
    Reichman, A.
    Yaar, A.
    Kushnir, M.
    Heldman, E.
    MOVEMENT DISORDERS, 2006, 21 : S603 - S604
  • [22] Paradoxical response to L-dopa and apomorphine in the Parkinson's disease
    García-Soldevilla, MA
    Puertas, I
    Barcenilla, B
    Sayed, Y
    García-Albea, E
    Jiménez-Jiménez, FJ
    MOVEMENT DISORDERS, 2002, 17 : S96 - S96
  • [23] Parkinson's disease, L-DOPA, and endogenous morphine: A revisit
    Stefano, George B.
    Mantione, Kirk J.
    Kralickova, Milena
    Ptacek, Radek
    Kuzelova, Hana
    Esch, Tobias
    Kream, Richard M.
    MEDICAL SCIENCE MONITOR, 2012, 18 (08): : RA133 - RA137
  • [24] L-DOPA for Parkinson's disease-a bittersweet pill
    Lane, Emma L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 384 - 398
  • [25] L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski, Janusz
    Nistico, Robert
    Berretta, Nicola
    Guatteo, Ezia
    Bernardi, Giorgio
    Mercuri, Nicola B.
    PROGRESS IN NEUROBIOLOGY, 2011, 94 (04) : 389 - 407
  • [26] Parkinson's disease: Progression and mortality in the L-DOPA era
    DiRocco, A
    Molinari, SP
    Kollmeier, B
    Yahr, MD
    PARKINSON'S DISEASE, 1996, 69 : 3 - 11
  • [27] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [28] Cabergoline improves motor disability without modifying L-DOPA plasma levels in fluctuating Parkinson's disease patients
    DelDotto, P
    Colzi, A
    Pardini, C
    Lucetti, C
    Dubini, A
    Grimaldi, R
    Bonuccelli, U
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 259 - 265
  • [29] MEASURING L-DOPA IN PLASMA AND URINE TO MONITOR THERAPY OF ELDERLY PATIENTS WITH PARKINSON DISEASE TREATED WITH L-DOPA AND A DOPA DECARBOXYLASE INHIBITOR
    DUTTON, J
    COPELAND, LG
    PLAYFER, JR
    ROBERTS, NB
    CLINICAL CHEMISTRY, 1993, 39 (04) : 629 - 634
  • [30] The effects of L-Dopa on attention in Parkinson's disease and Parkinson's dementia patients
    Molloy, S
    McKeith, IG
    Burn, D
    Wesnes, KA
    JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) : A51 - A51
12345